Waleed H. Hassanein Sells 30,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 30,000 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $130.07, for a total transaction of $3,902,100.00. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,017,905.01. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $128.77 on Friday. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $132.96. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. The firm has a market capitalization of $4.24 billion, a P/E ratio of -378.74 and a beta of 1.87. The company’s 50 day moving average price is $89.25 and its two-hundred day moving average price is $79.26.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The firm had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. During the same quarter last year, the business posted ($0.08) earnings per share. The company’s quarterly revenue was up 132.9% on a year-over-year basis. On average, equities analysts forecast that TransMedics Group, Inc. will post 0.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

TMDX has been the topic of a number of analyst reports. Piper Sandler restated an “overweight” rating and set a $120.00 target price (up previously from $95.00) on shares of TransMedics Group in a research report on Wednesday, May 1st. Morgan Stanley increased their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. TD Cowen increased their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Oppenheimer increased their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group increased their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $119.00.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently modified their holdings of the business. Blair William & Co. IL raised its stake in shares of TransMedics Group by 15.3% during the first quarter. Blair William & Co. IL now owns 183,524 shares of the company’s stock valued at $13,570,000 after acquiring an additional 24,417 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of TransMedics Group by 8.6% during the first quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock valued at $745,000 after acquiring an additional 780 shares during the last quarter. Entropy Technologies LP bought a new position in shares of TransMedics Group during the first quarter valued at $201,000. ProShare Advisors LLC raised its stake in shares of TransMedics Group by 7.8% during the first quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock valued at $434,000 after acquiring an additional 427 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after acquiring an additional 26,997 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.